Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : PLNI - Game Over -- Ignore unavailable to you. Want to Upgrade?

To: Captain James T. Kirk who wrote (30)	11/29/2005 9:44:58 AM
From: Harold S.	Read Replies (1) \| Respond to of 12518

I have called the company as recently as yesterday. My concerns are not so much this maze of patent numbers, but more, where are the press releases confirming the closings of the Promold and Semco Deals, as well as confirmation on the audit and the status of the reduction of outstanding shares. I have assured twice that all of the above has taken place or will take place by 12/31/05 and that we are simply in a quiet period waiting on "regulatory issues." We need to wait until all the "I's" have been dotted and the "T's" crossed on the move to the OTC before the flurry of PR's will begin!!

To: Captain James T. Kirk who wrote (30)	11/29/2005 9:52:17 AM
From: scion	Read Replies (2) \| Respond to of 12518

So you believe everything "the company" tells you? I asked you a question and if you don't like the question don't answer it. I also checked the USPTO site thoroughly for Turek's patents - have you? Meanwhile, I suggest you read this in its entirety - FINANCIAL REPORTING It’s no longer a matter of making a best estimate. Valuing IP Post-Sarbanes-Oxley -------------------------------------------------------------------------------- Before 2002, identifying and valuing intellectual property (IP) was more art than science. But in that year Congress passed the Sarbanes-Oxley Act and FASB issued new accounting standards for measuring and reporting on intangible assets. In this high-pressure environment CPAs will find IP valuation is no longer a matter of making a best estimate. As regulators begin to seek greater clarity in the asset values of publicly traded companies and require them to make more transparent disclosures, the onus is on CPAs to apply more scientific rigor to their IP valuations. But certifying with mathematical exactitude the full value of intangibles such as patents, brands, in-process research and other IP assets can be problematic. aicpa.org